An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia

Clinical Infectious Diseases

Volumn 51, Issue 9, 2010, Pages 1074-1080

  Bauer, Karri A ^a   West, Jessica E ^b   Balada Llasat, Joan Miquel ^a   Pancholi, Preeti ^a   Stevenson, Kurt B ^b   Goff, Debra A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; NAFCILLIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; BLOOD CULTURE; CONSULTATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; FEMALE; HEALTH CARE COST; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PHARMACIST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAPID POLYMERASE CHAIN REACTION; STAPHYLOCOCCACEAE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIOLOGICAL TECHNIQUES; BLOOD; DRUG PRESCRIPTIONS; DRUG THERAPY; HEALTH CARE COSTS; HUMANS; LENGTH OF STAY; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 77958556787     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656623     Document Type: Article

References (24)

1. US Department of Health and Human Services. HHS action plan to prevent healthcare-associated infections: Outreach and messaging [Internet]. Washington, DC: US Department of Health and Human Services. http://www.hhs.gov/ophs/ initiatives/hai/9-hai-plan-outreach.pdf. Accessed 27 January 2010.
2. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-177.
3. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: Implications for antibiotic stewardship. Clin Infect Dis 2009; 49(8):1175-1184.
4. Owens Jr. RC. Antimicrobial stewardship: Concepts and strategies in the 21st century. Diagn Microbiol Infect Dis 2008; 61:110-128.
5. National Nosocomial Infections Surveillance System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32(8):470-485.
6. Cosgrove SE, Qi Y, Kaye KS, Harnarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26(2):166-174.
7. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118(1):146-155. (Pubitemid 30485502)
8. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244(5):379-386. (Pubitemid 28513125)
9. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 39(4):539-545.
10. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42(6):2398-2402.
11. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52(4):1330-1336. (Pubitemid 351521995)
12. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: A lipopeptide antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother 2005; 55(3):283-188. (Pubitemid 40425449)
13. Stryjewski ME, Szczech LA, Bejamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44(2):190-196.
14. Wellinghausen N, Siegel D, Gerbert S, Winter J. Rapid detection of Staphylococcus aureus bacteremia and methicillin resistance by real-time PCR in whole blood samples. Eur J Clin Microbiol Infect Dis 2009; 28(8):1001-1005.
15. Wolk DM, Struelens MJ, Pancholi P, et al. Rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. J Clin Microbiol 2009; 47(3):823-826.
16. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36(11):1418-1423.
17. Carroll KC. Rapid diagnostics for methicillin-resistant Staphylococcus aureus: current status. Mol Diagn Ther 2008; 12(1):15-24.
18. Nguyen DT, Yeh E, Perry S, et al. Real-time PCR testing for mecA reduces vancomycin usage and length of hospitalization for patients infected with methicillin-sensitive staphylococci. J Clin Microbiol 2010; 48(3):785-790.
19. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004; 25(5):425-430.
20. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162(19):2229-2235.
21. Kim S, Kim K, Kim H, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52(1):192-197.
22. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46(5):1492-1502.
23. Lodise TP, Graves J, Evans AG, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52(4):1330-1336.
24. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355(7):653-665.